Publications by authors named "H Box"
Favipiravir (FVP) and remdesivir (RDV) have demonstrable antiviral activity against SARS-CoV-2. Here, the efficacy of FVP, RDV, and FVP with RDV (FVP + RDV) in combination was assessed in Syrian golden hamsters challenged with SARS-CoV- 2 (B.1.
View Article and Find Full Text PDFArticle Synopsis
- Global policymakers generally advise against using existing monoclonal antibodies like Ronapreve for COVID-19 treatment due to their reduced effectiveness against newer variants, especially Omicron.
- A study using K18-hACE2 mice showed that Ronapreve effectively reduced viral replication in the lungs and nasal areas for the Delta variant, but not for Omicron, and it prevented brain infection from Delta.
- Results indicated that Ronapreve alters the inflammatory response to the Delta variant, suggesting that while animal models can simulate treatment use cases, caution is needed in interpreting their relevance to actual treatment scenarios, particularly for Omicron.
Objective: The study evaluated physicochemical properties of eight different polymeric nanoparticles (NPs) and their interaction with lung barrier and their suitability for pulmonary drug delivery.
Methods: Eight physiochemically different NPs were fabricated from Poly lactic-co-glycolic acid (PLGA, PL) and Poly glycerol adipate-co-ω-pentadecalactone (PGA-co-PDL, PG) emulsification-solvent evaporation. Pulmonary barrier integrity was investigated using Calu-3 under air-liquid interface.
Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.
J Antimicrob Chemother
January 2024
Objectives: Antiviral interventions are required to complement vaccination programmes and reduce the global burden of COVID-19. Prior to initiation of large-scale clinical trials, robust preclinical data to support candidate plausibility are required. This work sought to further investigate the putative antiviral activity of probenecid against SARS-CoV-2.
View Article and Find Full Text PDFThe successful development of a chemoprophylaxis against SARS-CoV-2 could provide a tool for infection prevention that is implementable alongside vaccination programmes. Nafamostat is a serine protease inhibitor that inhibits SARS-CoV-2 entry in vitro, but it has not been characterised for chemoprophylaxis in animal models. Clinically, nafamostat is limited to intravenous delivery and has an extremely short plasma half-life.
View Article and Find Full Text PDF